Amended Current Report Filing (8-k/a)
15 November 2016 - 10:19PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
October
25, 2016
Date
of Report (Date of earliest event reported)
Immune
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Florida
|
|
000-54933
|
|
59-3226705
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.
|
37
North Orange Ave, Suite 607, Orlando, FL
|
|
32801
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
888-613-8802
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Explanatory
Note
This
Amended Current Report is being filed to amend the Current Report (“Current Report”), filed on November 2, 2016, in
order to re-attach the Exhibits originally included with the Current Report, as some pages of the Exhibits attached to the Current
Report were illegible or missing due to a filing error.
Item
1.01. Entry Into A Material Definitive Agreement.
On
October 25, 2016 Immune Therapeutics, Inc. and Acromax Dominicana, SA entered into a five year contract for manufacturing of LDN
tablets, capsules and/or creams. The agreement is attached hereto as Exhibit 10.1 and incorporated by reference.
On
October 31, 2016 Immune Therapeutics, Inc. and its wholly owned subsidiary TNI BioTech International, Ltd. on the one hand and
GB Pharma Holdings, LLC on the other amended and replaced their exclusive agency agreement dated June 12, 2014 and appointed GB
Pharma Holdings, LLC as the exclusive agent for Immune Therapeutics, Inc. in accordance with the terms of the October 31, 2016
agreement. The agreement is attached hereto as Exhibit 10.2 and incorporated by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits. The following exhibits are filed herewith.
Exhibit
No.
|
|
Description
|
|
|
|
10.1
|
|
Contract
for the Manufacturing of Pharmaceutical Products between Immune Therapeutics, Inc. and Acromax Dominicana, SA
|
|
|
|
10.2
|
|
Exclusive
Agency Agreement between Immune Therapeutics, Inc., TNI BioTech International, Ltd. and GB Pharma Holdings, LLC
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUNE
THERAPEUTICS, INC.
|
|
|
|
Date:
November 14, 2016
|
By:
|
/s/
Noreen Griffin
|
|
|
Noreen
Griffin, CEO
|
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2024 to May 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From May 2023 to May 2024